Related Experiment Video
Updated: Jan 15, 2026
06:51
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
8.1K
Recombinant human mitsugumin 53: a potential therapeutic agent for multiple diseases
Junfeng Li1, Jingjing Shen2, Tian Li3,4,5,6
1Department of Oncology of Zaozhuang Hospital of Zaozhuang Mining Group, Zaozhuang, Shandong, China.
Frontiers in Pharmacology
|October 8, 2025
Summary
Mitsugumin 53 (MG53) protein aids muscle repair and protects organs from injury. Recombinant human MG53 (rhMG53) shows therapeutic potential across various diseases, including cardiovascular and multiple-organ injuries.
Area of Science:
- Biochemistry
- Molecular Biology
- Regenerative Medicine
Background:
- Mitsugumin 53 (MG53) is a muscle-expressed protein vital for sarcolemmal membrane repair.
- MG53 also functions in non-striated tissues like lung, kidney, and immune cells.
- Endogenous MG53 plays a protective role in cardiac ischemia/reperfusion injury.
Purpose of the Study:
- To review the therapeutic functions of recombinant human MG53 (rhMG53).
- To elucidate the molecular mechanisms underlying rhMG53's protective effects in multiple organ injuries.
- To highlight rhMG53's potential as a therapeutic agent for diverse diseases.
Main Methods:
- Literature review of studies on MG53 and rhMG53.
- Analysis of molecular mechanisms in various disease models.
- Synthesis of evidence for rhMG53's broad therapeutic applications.
Main Results:
- rhMG53 demonstrates protective effects in skeletal muscle injury models.
- rhMG53 shows efficacy in cardiovascular disease and multiple-organ injury contexts.
- Studies confirm rhMG53's broad protective capabilities.
Conclusions:
- rhMG53 exhibits significant therapeutic potential for multiple organ injuries.
- Understanding rhMG53's mechanisms supports its development as a novel therapeutic agent.
- rhMG53 represents a promising candidate for treating a wide range of diseases.
